Literature DB >> 18342200

Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy.

Jeffrey K Cohen1, Ralph J Miller, Sharmila Ahmed, Meredith J Lotz, John Baust.   

Abstract

OBJECTIVES: Prostate cryosurgery has been increasingly used for the management of localized prostate cancer since its introduction in a minimally invasive form in the early 1990s. We performed a retrospective study of the largest and most mature patient group treated with cryosurgery reported thus far.
METHODS: We retrospectively analyzed the data from 370 patients treated consecutively from 1991 to 1996 with a focus on the determination of biochemical disease-free survival for a group of patients with T1 to T3 prostate cancer who had undergone prostate cryosurgery as primary monotherapy. Only patients with no previous radiotherapy, hormonal therapy, or surgery were included.
RESULTS: The median follow-up was 12.55 years. Using a nadir plus 2 ng/dL definition, Kaplan-Meier analysis demonstrated a biochemical disease-free survival rate at 10 years of 80.56%, 74.16%, and 45.54% for low, moderate, and high-risk groups, respectively. The 10-year negative biopsy rate was 76.96%.
CONCLUSIONS: The results for this pilot group of patients who underwent percutaneous prostate cryosurgery monotherapy demonstrated biochemical disease-free survival rates that overlap with those of similar groups of patients treated under similar circumstances using other types of nonextirpative monotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342200     DOI: 10.1016/j.urology.2007.09.059

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  31 in total

1.  Analysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer.

Authors:  Tong-Guo Si; Jun-Ping Wang; Zhi Guo
Journal:  Asian J Androl       Date:  2013-06-03       Impact factor: 3.285

Review 2.  [Cryoablation of localized prostate cancer. Current state].

Authors:  U K F Witzsch; E Becht
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

3.  Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis.

Authors:  John M Baust; Daniel P Klossner; Anthony Robilotto; Robert G Vanbuskirk; Andrew A Gage; Vladimir Mouraviev; Thomas J Polascik; John G Baust
Journal:  BJU Int       Date:  2011-08-26       Impact factor: 5.588

4.  Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.

Authors:  Henk van der Poel; Laurence Klotz; Gerald Andriole; Abdel-Rahmène Azzouzi; Anders Bjartell; Olivier Cussenot; Freddy Hamdy; Markus Graefen; Paolo Palma; Arturo Rodriguez Rivera; Christian G Stief
Journal:  World J Urol       Date:  2015-06-03       Impact factor: 4.226

5.  Effects of Focal vs Total Cryotherapy and Minimum Tumor Temperature on Patient-reported Quality of Life Compared With Active Surveillance in Patients With Prostate Cancer.

Authors:  Glenn T Werneburg; Michael Kongnyuy; Daniel M Halpern; Jose M Salcedo; Connie Chen; Amanda LeSueur; Kaitlin E Kosinski; Jeffrey T Schiff; Anthony T Corcoran; Aaron E Katz
Journal:  Urology       Date:  2017-12-23       Impact factor: 2.649

Review 6.  Re-purposing cryoablation: a combinatorial 'therapy' for the destruction of tissue.

Authors:  J G Baust; J C Bischof; S Jiang-Hughes; T J Polascik; D B Rukstalis; A A Gage; J M Baust
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-01-27       Impact factor: 5.554

Review 7.  Experimental cryosurgery investigations in vivo.

Authors:  A A Gage; J M Baust; J G Baust
Journal:  Cryobiology       Date:  2009-10-13       Impact factor: 2.487

Review 8.  Mechanisms of cryoablation: clinical consequences on malignant tumors.

Authors:  J G Baust; A A Gage; T E Bjerklund Johansen; J M Baust
Journal:  Cryobiology       Date:  2013-11-13       Impact factor: 2.487

9.  Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy.

Authors:  M Ismail; S Bokaee; Richard Morgan; J Davies; K J Harrington; H Pandha
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

10.  Integrin involvement in freeze resistance of androgen-insensitive prostate cancer.

Authors:  J G Baust; D P Klossner; R G Vanbuskirk; A A Gage; V Mouraviev; T J Polascik; J M Baust
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-01-12       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.